Abstract
Major risk factors for clinical atherosclerosis include dyslipidemia, hypertension, glucose intolerance, adiposity, cigarette smoking, hemostatic factors, inflammatory markers, and sedentary lifestyle. Sets of some of these and evidence of vascular damage such as left ventricular hypertrophy and atrial fibrillation are used to formulate multivariable risk profiles for peripheral artery disease and stroke. These global risk formulations facilitate office estimation of the risk of these disabling diseases, which often indicate diffuse systemic atherosclerosis. Because predisposing risk factors usually cluster, and the risk each imposes varies widely, global risk assessment is a necessity, especially now that average risk factor levels are recommended for treatment. Novel risk factors deserve attention, but the standard cardiovascular risk factors account for as much as 85% of the cardiovascular disease arising within the population. Further improvement in detection, evaluation, and control of the major risk factors by implementation of guidelines for primary and secondary prevention of stroke and peripheral artery disease is needed, particularly in the high-risk segment of the population.
Similar content being viewed by others
References and Recommended Reading
Cupples LA, D’Agostino RB: Survival Following Initial Cardiovascular Events. The Framingham Study. 30-year follow-up. Section 35. NIH Publication No. 88-2909, 1988.
Kannel WB: Global cardiovascular risk evaluation. In Preventive Cardiology. A Practical Approach, edn 2. Edited by Wong ND, Black HR, Gardin JM. New York: McGraw-Hill; 2005:1–21.
2002 NHLBI Chart Book on Cardiovascular Lung and Blood Diseases.
Hiatt WR: Medical treatment of peripheral arterial disease. N Engl J Med 2001, 344:1608–1621.
Thom TJ: Stroke mortality trends: an international perspective. Ann Epidemiol 1993, 3:509–518.
American heart Association 2004 Heart Disease and Stroke Statistics-2004 Update. Dallax, TX: American Heart Association; 2004.
Hylek EM, Go AS, Chang Y, et al.: Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003, 349:1019–1026.
Kannel WB, McGee DL: Update on some epidemiologic features of intermittent claudication. J Am Geriatr Soc 1985, 33:13–18.
Kannel WB: Risk factors for atherosclerotic cardiovascular outcomes in different vascular territories. J Cardiovasc Risk 1994, 1:1–7.
Murabito JM, Evans JC, D’Agostino RB, et al.: Temporal trends of intermittent claudication from 1950–1999. Am J Epidemiol 2005, 162:430–437.
Hackam DG, Goodman SG, Annand SS: Management of risk in peripheral artery disease: Recent therapeutic advances. Am Heart J 2005, 150:35–40.
Sacco RL, Benjamin EJ, Broderick JP, et al.: Risk factors. Stroke 1997, 28:1507–1517.
Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991, 22:983–988.
Benjamin EJ, Plehn JF, D’Agostino RB, et al.: Mitral annular calcification and risk of stroke in an elderly cohort. N Engl J Med 1992, 327:374–379.
Kannel WB, Wolf PA, Verter J: Manifestations of coronary disease predisposing to stroke. JAMA 1983, 250:2942–2946.
Sacco RL, Foulkes MA, Mohr JP, et al.: Determinants of early recurrence of cerebral infarction: the Stroke Data Bank. Stroke 1989, 20:983–989.
Sacco RL, Wolf PA, Kannel WB, McNamara PM: Survival and recurrence following stroke: the Framingham Study. Stroke 1982, 13:290–295.
Sacco RL, Shi T, Zamanillo MC, Kargman DE: Predictors of mortality and recurrence after hospitalized cerebral infarction in an urban community: the Northern Manhattan Stoke Study. Neurology 1994, 44:626–634.
Kannel WB: Epidemiologic relation of cardiovascular disease among different vascular territories. In Atherothrombosis and Coronary Artery Disease, edn 2. Edited by Fuster V, Topol EJ, Nabel EG: Philadelphia: Lippincott Williams & Wilkins; 2005:1493–1496.
Wolf PA, Kannel WB, Sorlie P, McNamara P: Asymptomatic carotid bruit and risk of stroke. The Framingham Study. JAMA 1981, 245:1442–1445.
Kase CS, Wolf PA, Chodosh EH, et al.: Prevalence of silent stroke in patients presenting with initial stroke: the Framingham Study. Stroke 1989, 20:850–852.
Chodosh EH, Foulkes MA, Kase CS, et al.: Silent stroke in the NINCDS Stroke Data Bank. Neurology 1998, 38:1674–1679.
Manolio TA, Kronmal RA, Burke GL, et al.: Magnetic resonance abnormalities and cardiovascular disease in older adults. Stroke 1994, 25:318–327.
Vermeer SF, Prins ND, Den Heijer T, et al.: Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003, 348:1215–1222.
Giele JL, Witkamp TD, Mali WP, van der Graaf Y: Silent brain infarcts in patients with manifest vascular disease. Stroke 2004, 35:742.
Murabito JM, Evans JC, Larson MG, et al.: The Ankle-Brachial Index in the elderly and risk of stroke, coronary disease and death. The Framingham Study. Arch Intern Med 2003, 163:1939–1942.
Franklin SS, Kahn SA, Wong ND, et al.: Is pulse pressure useful in predicting risk for coronary heart disease? Circulation 1999, 100:354–360.
O’Leary DH, Anderson KM, Wolf PA, et al.: Cholesterol and carotid atherosclerosis. The Framingham Study. Ann Epidemiol 1992, 2:147–153.
Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events trial investigators. N Engl J Med 1996, 335:1001–1029.
Wolf PA, D’Agostino RB, Bonita R, Belanger AJ: Cigarette smoking as a risk factor for stroke. The Framingham study. JAMA 1988, 259:1025–1029.
Fowler B, Jamrozik K, Norman P, Allen Y: Prevalence of peripheral arterial disease; persistence of excess risk in former smokers. Aust NZ J Pub Health 2002, 26:219–224.
Reaven GM: Syndrome X: 6 years later. J Intern Med 1995, 736:13–22.
Moller DE, Kaufman KD: Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005, 56:45–62.
Najarian RM, Sullivan LM, Wilson PW, et al.: Impact of the metabolic syndrome compared to diabetes as a risk factor for stroke. Arch Intern Med 2006, 166:106–111.
Wilson PW, D’Agostino RB, Levy D, et al.: Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837–1847.
Brand RJ, Rosenman RH, Sholtz RI, Friedman M: Multivariate prediction of coronary heart disease in the Western Collaborative Group Study compared to the findings of the Framingham Study. Circulation 1976, 53:348–355.
Leaverton PE, Sorlie PD, Kleinman JC, et al.: Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. J Chronic Dis 1987, 40:775–784.
McGee D, Gordon T: The results of the Framingham Study applied to four other US-based studies of cardiovascular disease. In The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease, section 31. Edited by Kannel WB, Gordon T. US Dept of Health Education and Welfare publication No. 76-1083. Bethesda, MD: US Government Printing Office; 1976.
Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB: Probability of stroke: a risk profile from the Framingham Study. Stroke 1991, 22:312–318.
Murabito JM, D’Agostino RB, Silbershatz H, Wilson PW: Intermittent claudication: a risk profile from the Framingham Study. Circulation 1997, 96:44–49.
Murabito JM, Evans JC, Nieto K, et al.: Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002, 143:961–965.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kannel, W.B., Wolf, P.A. Peripheral and cerebral atherothrombosis and cardiovascular events in different vascular territories: Insights from the framingham study. Curr Atheroscler Rep 8, 317–323 (2006). https://doi.org/10.1007/s11883-006-0010-3
Issue Date:
DOI: https://doi.org/10.1007/s11883-006-0010-3